Civic Intelligence

Abzyme Research Foundation

EIN 27-3438658 • 501(c)3 • New York, NY

Profile

Advance the development of abzyme technology in the hopes of producing the world's first effective hiv vaccine and improved treatment for over 36 million hiv-positive people worldwide.

210 11th Ave 503New York, NY 10011

www.endhiv.com

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2024

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2024

Net Margin

93rd percentile

63%

Higher net margin than 93% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2024

Top Officer Pay

84th percentile

$0

Higher top officer pay than 84% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

501(c)3 • <$500k nonprofits • Source year 2023

Asset Growth

58th percentile

1.9%

Faster asset growth than 58% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2023 to 2024

Revenue Growth

100th percentile

43383%

Faster revenue growth than 100% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2023 to 2024

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Up

$335,298

Up $6,319 (+1.9%) from 2023

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Up

$335,298

Up $6,319 (+1.9%) from 2023

Operations
Liabilities / RevenueScore unavailableNet Margin93rd percentile

Revenue

Up

$10,001

Up $9,978 (+43383%) from 2023

Expenses

Down

$3,682

Down $3,541 (-49%) from 2023

Net Income

Up

$6,319

Up $13,519 (+188%) from 2023

Trend Graphs

Balance Sheet Trend

Asset Growth58th percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

$400K$300K$200K$100K$0Assets 2017: $385,535Liabilities 2017: $2,215Net Assets 2017: $383,3202017Assets 2018: $351,372Liabilities 2018: $10,750Net Assets 2018: $340,6222018Assets 2019: $353,342Liabilities 2019: $0Net Assets 2019: $353,3422019Assets 2020: $344,776Liabilities 2020: $0Net Assets 2020: $344,7762020Assets 2021: $341,865Liabilities 2021: $0Net Assets 2021: $341,8652021Assets 2022: $336,178Net Assets 2022: $336,1782022Assets 2023: $328,979Net Assets 2023: $328,9792023Assets 2024: $335,298Net Assets 2024: $335,2982024

Highlighted filing

2024

Assets$335,298
Liabilities-
Net Assets$335,298
Open 2024 Filing

Operations Trend

Revenue Growth100th percentile

Revenue, expenses, and net income by year, with the latest filing highlighted.

$1.0M$500K$0-$500K-$1.0MRevenue 2017: $172,225Expenses 2017: $744,547Net Income 2017: -$572,3222017Revenue 2018: $84,666Expenses 2018: $127,364Net Income 2018: -$42,6982018Revenue 2019: $60,108Expenses 2019: $32,293Net Income 2019: $27,8152019Revenue 2020: $5,394Expenses 2020: $13,960Net Income 2020: -$8,5662020Revenue 2021: $139Expenses 2021: $3,050Net Income 2021: -$2,9112021Revenue 2022: $52Expenses 2022: $5,739Net Income 2022: -$5,6872022Revenue 2023: $23Expenses 2023: $7,223Net Income 2023: -$7,2002023Revenue 2024: $10,001Expenses 2024: $3,682Net Income 2024: $6,3192024

Highlighted filing

2024

Revenue$10,001
Expenses$3,682
Net Income$6,319
Open 2024 Filing

Filings

Most recent year

2024 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$335,298
Liabilities
-
Net assets
$335,298
Revenue
$10,001
Expenses
$3,682
Net income
$6,319
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$3.35$3.35$0.10$0.04$0.06
2023Detailed filing. Detailed filing data is available for this year.$3.29$3.29$0.00$0.07$0.07
2022Detailed filing. Detailed filing data is available for this year.$3.36$3.36$0.00$0.06$0.06
2021Detailed filing. Detailed filing data is available for this year.$3.42$0.00$3.42$0.00$0.03$0.03
2020Detailed filing. Detailed filing data is available for this year.$3.45$0.00$3.45$0.05$0.14$0.09
2019Detailed filing. Detailed filing data is available for this year.$3.53$0.00$3.53$0.60$0.32$0.28
2018Detailed filing. Detailed filing data is available for this year.$3.51$0.11$3.41$0.85$1.27$0.43
2017Detailed filing. Detailed filing data is available for this year.$3.86$0.02$3.83$1.72$7.45$5.72
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
Jul 9, 2025
Return Version
2024v5.2
Gross Receipts
$10,001
Mission and Program Overview

Mission

Advance the development of abzyme technology in the hopes of producing the world's first effective hiv vaccine and improved treatment for over 36 million hiv-positive people worldwide.

The successful completion of the pre-investigational new drug meeting with the fda as wellas the initiation of a scale-up of the manufacturing of the vaccine compound.

Program Services

DescriptionGrantsExpenses
ADVANCE THE DEVELOPMENT OF ABZYME TECHNOLOGY IN THE HOPES OF PRODUCING THE WORLD'S FIRST EFFECTIVE HIV VACCINE AND IMPROVED TREATMENT FOR OVER 36 MILLION HIV POSITIVE PEOPLE WORLDWIDE--
Compensation and Service Providers
Top Officer Pay84th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
ZACHARY BARNETTDirector-$0--
VALERIE KERRDirector-$0--
BETH MILLER SAKSDirector-$0--
TIM VOLKDirector-$0--
ADAM MACLEANChairman-$0--
MICHAEL JEFVERTChairman-$0--
AIMEE A DROUINSecretary-$0--
NICHOLAS SMITHTreasurer-$0--
Filing and Contact Details

Filer

Filer Name
Abzyme Research Foundation
EIN
27-3438658
Phone
3479673734
Address
210 11th Ave 503, NEW YORK, NY 10011

Signing Officer

Name
Zachary Barnett
Title
Director
Signed
2025-07-09
Discuss with paid preparer
Yes

Preparer

Firm
George Dimov CPA
Address
211 E 43rd Street Suite 628, NEW YORK, NY 10017
Preparer
George Dimov CPA
Phone
8338291120
Supplemental Narrative

Additional Explanations

Other Expenses.1005

“Travel $508”

Other Expenses.1

“Software and Apps $1459”

Other Expenses.2

“Charitable contribution $765”

Other Expenses.3

“Bank Charges $710”

Other Assets.1

“Investment in Covalent Bioscience - Beginning $265658 Investment in Covalent Bioscience - Ending $265658”

Other Assets.2

“American Express Credit Card - Beginning $2825 American Express Credit Card - Ending $0”

Other Assets.3

“Adjustment to assets after the reconc - Beginning $0 Adjustment to assets after the reconc - Ending $39047”

Raw XML Appendix158 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/AddressChangeInd0X
IRS990EZ/BooksInCareOfDetail/PersonNm0THE ORGANIZATION
IRS990EZ/BooksInCareOfDetail/PhoneNum03479673734
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0210 11th Ave Suite 503
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0NEW YORK
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0NY
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd010011
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt060496
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt030593
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt010000
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt06319
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt0240
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0328979
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0335298
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt010001
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt01
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NameChangeInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0328979
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0335298
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0328979
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0335298
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt11.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt61.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt71.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0ZACHARY BARNETT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1VALERIE KERR
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2BETH MILLER SAKS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3TIM VOLK
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4ADAM MACLEAN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5MICHAEL JEFVERT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6AIMEE A DROUIN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7NICHOLAS SMITH
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Chairman
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Chairman
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7Treasurer
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherAssetsTotalDetail/BOYAmt0268483
IRS990EZ/OtherAssetsTotalDetail/EOYAmt0304705
IRS990EZ/OtherExpensesTotalAmt03442
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0THE SUCCESSFUL COMPLETION OF THE PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE FDA AS WELLAS THE INITIATION OF A SCALE-UP OF THE MANUFACTURING OF THE VACCINE COMPOUND.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0ADVANCE THE DEVELOPMENT OF ABZYME TECHNOLOGY IN THE HOPES OF PRODUCING THE WORLD'S FIRST EFFECTIVE HIV VACCINE AND IMPROVED TREATMENT FOR OVER 36 MILLION HIV POSITIVE PEOPLE WORLDWIDE
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt03682
IRS990EZ/TotalRevenueAmt010001
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.ENDHIV.COM
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt010000
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt010000
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt00
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.00000
IRS990ScheduleA/PublicSupportTotal170Amt010000
IRS990ScheduleA/SubstantialContributorsTotAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt010000
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt010000
IRS990ScheduleA/TotalSupportAmt010000
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Travel $508
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Software and Apps $1459
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Charitable contribution $765
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Bank Charges $710
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4Investment in Covalent Bioscience - Beginning $265658 Investment in Covalent Bioscience - Ending $265658
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5American Express Credit Card - Beginning $2825 American Express Credit Card - Ending $0
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6Adjustment to assets after the reconc - Beginning $0 Adjustment to assets after the reconc - Ending $39047
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Expenses.1005
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.3
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Assets.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Assets.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6Other Assets.3
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0ZACHARY BARNETT
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-07-09
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0ABZYME RESEARCH FOUNDATION
ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt0co Jamie Drake Design
ReturnHeader/Filer/BusinessNameControlTxt0ABZY
ReturnHeader/Filer/EIN0273438658
ReturnHeader/Filer/PhoneNum03479673734
ReturnHeader/Filer/USAddress/AddressLine1Txt0210 11th Ave 503
ReturnHeader/Filer/USAddress/CityNm0NEW YORK
ReturnHeader/Filer/USAddress/StateAbbreviationCd0NY
ReturnHeader/Filer/USAddress/ZIPCd010011
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0true
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0823109419
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0George Dimov CPA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0211 E 43rd Street Suite 628
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0NEW YORK
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NY
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd010017
ReturnHeader/PreparerPersonGrp/PhoneNum08338291120
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0GEORGE DIMOV CPA
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02025-07-09T11:25:20-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-01-01
ReturnHeader/TaxPeriodEndDt02024-12-31
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.